Study of VYD2311 for the Prevention of COVID-19
Trial details
- Registry ID
- NCT07298434
- Drugs studied
- VYD2311-MD, VYD2311-SD
TrialRedline tracks 6 clinical trials sponsored by Invivyd, Inc.: 3 Phase 3, 2 Phase 2 / 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of VYD2311 for the Prevention of COVID-19NCT07298434 | VYD2311-MD, VYD2311-SD | Active not recruiting | 2026-08Estimated |
| Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccineNCT07655180 | COVID-19 mRNA vaccine, VYD2311 | Completed | 2026-08-15Actual |
| A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2NCT06039449 | Normal saline, VYD222 (pemivibart) | Completed | 2024-11-19Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Evaluation of ADG20 for the Prevention of COVID-19NCT04859517 | ADG20 | Terminated | 2022-11-04Actual |
| Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19NCT04805671 | ADG20, Normal saline | Terminated | 2022-02-10Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination SyndromeNCT07899346 | VYD2311 | Not yet recruiting | 2027-06Estimated |
Names as written in the registry records.
Before: Estimated. After: Actual.
Before: Estimated. After: Actual.
Before: Aug 2026. After: 15 Aug 2026.
Before: Recruiting. After: Completed.
NCT07298434 · Invivyd, Inc.
Before: Recruiting. After: Active not recruiting.
NCT07298434 · Invivyd, Inc.
Before: Mar 2026. After: Aug 2026.
Before: Active not recruiting. After: Recruiting.
NCT07298434 · Invivyd, Inc.
Before: Recruiting. After: Active not recruiting.
NCT07298434 · Invivyd, Inc.
Before: Not yet recruiting. After: Recruiting.